Cipher Pharmaceuticals Inc. (TSE:CPH – Free Report) (NASDAQ:CPHR) – Investment analysts at Leede Financial dropped their FY2025 earnings estimates for shares of Cipher Pharmaceuticals in a report released on Monday, August 11th. Leede Financial analyst D. Loe now expects that the company will earn $0.86 per share for the year, down from their prior forecast of $0.87. The consensus estimate for Cipher Pharmaceuticals’ current full-year earnings is $1.29 per share. Leede Financial also issued estimates for Cipher Pharmaceuticals’ FY2026 earnings at $0.97 EPS.
Cipher Pharmaceuticals Stock Down 3.8%
CPH stock opened at C$14.40 on Wednesday. Cipher Pharmaceuticals has a 12-month low of C$10.61 and a 12-month high of C$19.69. The company has a quick ratio of 2.67, a current ratio of 2.00 and a debt-to-equity ratio of 41.22. The company has a market cap of C$258.53 million, a price-to-earnings ratio of 15.90 and a beta of 1.20. The company has a 50 day moving average of C$13.04 and a two-hundred day moving average of C$12.71.
Cipher Pharmaceuticals Company Profile
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company’s geographical segments include Canada and the United States.
Further Reading
- Five stocks we like better than Cipher Pharmaceuticals
- How to trade penny stocks: A step-by-step guide
- How Did Peter Thiel-Backed Crypto Exchange Bullish’s IPO Go?
- Compound Interest and Why It Matters When Investing
- Mercury Systems Up 27%: Financials Send Investors a Clear Signal
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Deere’s Sell-Off Could Be a Long-Term Buying Chance
Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
